Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.

@article{Ishikawa2007CancertestisAL,
  title={Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.},
  author={Nobuhisa Ishikawa and Atsushi Takano and Wataru Yasui and Kouki Inai and Hitoshi Nishimura and Hiroyuki Ito and Yohei Miyagi and Haruhiko Nakayama and Masahiro Fujita and Masao Hosokawa and Eiju Tsuchiya and Nobuoki Kohno and Yusuke Nakamura and Yataro Daigo},
  journal={Cancer research},
  year={2007},
  volume={67 24},
  pages={
          11601-11
        }
}
Gene expression profile analyses of non-small cell lung carcinomas (NSCLC) and esophageal squamous cell carcinomas (ESCC) revealed that lymphocyte antigen 6 complex locus K (LY6K) was specifically expressed in testis and transactivated in a majority of NSCLCs and ESCCs. Immunohistochemical staining using 406 NSCLC and 265 ESCC specimens confirmed that LY6K overexpression was associated with poor prognosis for patients with NSCLC (P = 0.0003), as well as ESCC (P = 0.0278), and multivariate… 
View on PubMed
cancerres.aacrjournals.org
111 Citations
Highly Influential Citations
6
Background Citations
34
Methods Citations
7
Results Citations
3

111 Citations

Citation Type

Citation Type

Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma
Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer.
TLDR
It is found that serum Nectin-4 levels were significantly higher in NSCLC patients than in healthy volunteers and should be a new candidate serum and tissue biomarker, as well as a therapeutic target.
Cancer‐testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer
TLDR
BORIS may be a useful biomarker for prognostic diagnosis of ESCC patients and a potential target for treatment including by BORIS‐specific immunotherapy and molecular target therapy.
Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis
TLDR
OIP5 expression was significantly associated with poor prognosis of lung and esophageal cancer patients, and multivariate analysis confirmed its independent prognostic value for non‐small cell lung cancers.
Activation of Placenta-Specific Transcription Factor Distal-less Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients
TLDR
DLX5 gene, a member of the human distal-less homeobox transcriptional factor family that is expressed during early embryonic development, was found to be overexpressed in the great majority of lung cancers.
Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma
TLDR
Autoantibodies against LY6K may be a good diagnostic biomarker for ESCC and were found significantly higher in patients than controls.
Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis
TLDR
WDHD1 expression is likely to play an important role in lung and esophageal carcinogenesis as a cell cycle regulator and a downstream molecule in the phosphoinositide 3-kinase/AKT pathway, and that WDHD1 is a candidate biomarker and a promising therapeutic target for cancer.
Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression
TLDR
ECT2 cancer-testis antigen is likely to be a prognostic biomarker in clinic and a potential therapeutic target for the development of anticancer drugs and cancer vaccines for lung and esophageal cancers.
ORAOV1 overexpression in esophageal squamous cell carcinoma and esophageal dysplasia: a possible biomarker of progression and poor prognosis in esophageal carcinoma.
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer
TLDR
Since MCM7 expression was generally low in a number of normal tissues it has the characteristics of an ideal candidate for molecular targeted cancer therapy in various tumors and also as a good prognostic biomarker for NSCLC patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas.
TLDR
The data imply that DKK1 should be useful as a novel diagnostic/prognostic biomarker in clinic and probably as a therapeutic target for lung and esophageal cancer.
ADAM8 as a Novel Serological and Histochemical Marker for Lung Cancer
TLDR
The data suggest that ADAM8 should be useful as a diagnostic marker and probably as a therapeutic target, and exogenous expression ofADAM8 increased the migratory activity of mammalian cells, an indication that ADAMI may play a significant role in progression of lung cancer.
CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group.
Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer.
TLDR
Evidence is reported that a member of the armadillo protein family, plakophilin 3 (PKP3), is a potential molecular target for treatment of lung cancers and might also serve as a prognostic indicator.
Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer
TLDR
Data strongly implied that targeting the KIF4A molecule might hold a promise for the development of anticancer drugs and cancer vaccines as well as a prognostic biomarker in clinic.
Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas.
TLDR
Gen expression profile analysis of 19 esophageal squamous cell carcinoma cells purified by laser microbeam microdissection demonstrated transactivation of a secretory protein, transforming growth factor alpha (TGFA) in the great majority of 228 ESCC cases and an association of their expression with the poor prognosis of patients.
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
TLDR
Analysis of cDNA microarray analysis of NSCLCs after laser-capture microdissection identified 40 genes whose expression levels could separate cases with lymph-node metastasis from those without metastasis and provide valuable information for eventually identifying predictive markers and novel therapeutic target molecules for this type of cancer.
The cancer/testis genes: review, standardization, and commentary.
TLDR
A CT gene database was created to standardize CT nomenclature and accumulate relevant data regarding their expression profiles, immunogenicity, function (where known), gene structure and location, and orthologous groups.
Identification of COX17 as a therapeutic target for non-small cell lung cancer.
TLDR
Evidence is reported that the cytochrome c oxidase (CCO) assembly protein COX17 is a potential molecular target for treatment of lung cancers and that selective suppression of components of the CCO complex might hold promise for development of a new strategy for treating lung cancers.
Characterization of SEZ6L2 cell‐surface protein as a novel prognostic marker for lung cancer
TLDR
Results indicate that SEZ6L2 should be a useful prognostic marker of lung cancers, using cDNA microarrays coupled with purification of tumor cells by laser microdissection.
...
1
2
3
4
5
...